ICD-10 Coding for Elevated Carcinoma Antigen 19-9(C25.9, C25.9B, C25.9M)
Learn about the ICD-10 coding for elevated CA 19-9, including when to use R97.2 and C25.9, documentation requirements, and common pitfalls.
Complete code families applicable to Elevated Carcinoma Antigen 19-9
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| R97.2 | Elevated tumor associated antigen | Use when CA 19-9 is elevated but no malignancy is confirmed after thorough investigation. |
|
| C25.9 | Malignant neoplasm of pancreas, unspecified | Use when pancreatic cancer is confirmed and CA 19-9 is used for monitoring. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutElevated Carcinoma Antigen 19-9
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Elevated Carcinoma Antigen 19-9.
Failing to document malignancy workup
Impact
Clinical: May lead to inappropriate treatment decisions., Regulatory: Non-compliance with documentation standards., Financial: Potential claim denials.
Mitigation
Ensure complete documentation of diagnostic workup.
Using R97.2 as a primary code for confirmed malignancy
Impact
Reimbursement: Claims may be denied or reimbursed at a lower rate., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate cancer registry data.
Mitigation
Use the specific malignancy code (e.g., C25.9) as primary.
Improper use of R97.2
Impact
Using R97.2 without documented malignancy exclusion.
Mitigation
Ensure thorough documentation of negative malignancy workup.